Catalyst Pharmaceuticals/CPRX

$15.34

-4.12%
-
1D1W1MYTD1YMAX

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Ticker

CPRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Daly

Employees

167

Headquarters

Coral gables, United States

CPRX Metrics

BasicAdvanced
$1.89B
Market cap
26.26
P/E ratio
$0.61
EPS
0.87
Beta
-
Dividend rate
$1.89B
0.87227
$17.78
$11.09
1.27M
2.884
2.678
16.822
16.89%
20.75%
20.06%
26.263
4.742
4.419
9.741
13.17
85.9%
-18.22%
49.54%
-3.83%

What the Analysts think about CPRX

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
74.12% upside
High $34.00
Low $22.00
$15.34
Current price
$26.71
Average price target

CPRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
31.49% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$110.5M
7.7%
Net income
$34.8M
-213.36%
Profit margin
31.49%
-205.25%

CPRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.98%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.26
$0.33
-$0.29
$0.31
-
Expected
$0.32
$0.36
-$0.29
$0.27
$0.17
Surprise
-19.25%
-7.3%
1.75%
16.98%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals (CPRX) has a market cap of $1.89B as of April 19, 2024.

What is the P/E ratio for Catalyst Pharmaceuticals stock?

The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 26.26 as of April 19, 2024.

Does Catalyst Pharmaceuticals stock pay dividends?

No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Catalyst Pharmaceuticals dividend payment date?

Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Catalyst Pharmaceuticals stock price target?

The target price for Catalyst Pharmaceuticals (CPRX) stock is $26.71, which is 74.12% above the current price of $15.34. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Catalyst Pharmaceuticals stock

Buy or sell Catalyst Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing